Your browser is no longer supported. Please, upgrade your browser.
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Index- P/E15.62 EPS (ttm)0.66 Insider Own1.70% Shs Outstand160.07M Perf Week-3.64%
Market Cap1.68B Forward P/E9.86 EPS next Y1.05 Insider Trans439.05% Shs Float155.36M Perf Month-8.88%
Income106.20M PEG- EPS next Q0.20 Inst Own- Short Float13.20% Perf Quarter-11.35%
Sales389.50M P/S4.32 EPS this Y74.90% Inst Trans-0.50% Short Ratio8.93 Perf Half Y-1.72%
Book/sh0.39 P/B26.44 EPS next Y8.96% ROA22.40% Target Price11.00 Perf Year4.78%
Cash/sh2.22 P/C4.64 EPS next 5Y- ROE- 52W Range8.63 - 12.55 Perf YTD-9.48%
Dividend- P/FCF10.08 EPS past 5Y21.60% ROI28.50% 52W High-15.70% Beta1.38
Dividend %- Quick Ratio- Sales past 5Y21.10% Gross Margin99.20% 52W Low22.60% ATR0.40
Employees232 Current Ratio15.40 Sales Q/Q-7.60% Oper. Margin36.70% RSI (14)49.35 Volatility3.07% 3.49%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.50% Profit Margin27.30% Rel Volume0.42 Prev Close10.31
ShortableYes LT Debt/Eq6.87 EarningsFeb 17 BMO Payout0.00% Avg Volume2.30M Price10.58
Recom2.60 SMA20-2.53% SMA501.78% SMA2000.99% Volume475,948 Change2.62%
Sep-30-20Downgrade Wells Fargo Overweight → Equal Weight $14 → $9
Jun-17-20Initiated Northland Capital Outperform $14
Jul-10-19Resumed Credit Suisse Neutral
Mar-27-19Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-19Upgrade H.C. Wainwright Sell → Neutral $14
Jan-24-19Upgrade JP Morgan Underweight → Neutral
Nov-07-18Downgrade JP Morgan Neutral → Underweight
Nov-07-18Downgrade Credit Suisse Outperform → Neutral
Jul-23-18Initiated H.C. Wainwright Sell $12.50
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Mar-19-21 11:30AM  
Mar-01-21 06:40AM  
Feb-27-21 06:15AM  
Feb-19-21 04:01PM  
Feb-17-21 12:00PM  
07:48AM  
07:01AM  
06:30AM  
Feb-10-21 12:31PM  
Feb-09-21 08:09AM  
04:58AM  
Feb-08-21 04:01PM  
03:18AM  
Feb-03-21 04:01PM  
Jan-05-21 07:30AM  
Dec-05-20 11:32AM  
Dec-04-20 08:44AM  
Dec-03-20 08:30AM  
Nov-30-20 01:39PM  
Nov-27-20 12:20PM  
08:57AM  
08:36AM  
Nov-07-20 12:31AM  
Nov-06-20 04:01PM  
10:00AM  
09:43AM  
Nov-05-20 07:05PM  
04:03PM  
04:01PM  
02:30PM  
09:23AM  
Oct-29-20 12:35PM  
Oct-22-20 04:01PM  
12:33PM  
Sep-30-20 11:08AM  
Sep-29-20 08:55AM  
07:15AM  
Sep-27-20 07:33AM  
Sep-14-20 10:55PM  
Sep-05-20 11:31AM  
Sep-02-20 04:00PM  
Aug-26-20 12:20PM  
Aug-07-20 02:52PM  
11:18AM  
Aug-06-20 10:45AM  
07:00AM  
Jul-30-20 12:33PM  
Jul-23-20 04:05PM  
12:17PM  
Jul-21-20 07:00AM  
Jul-12-20 07:40PM  
Jun-08-20 02:51AM  
Jun-05-20 11:31AM  
Jun-03-20 09:56AM  
09:04AM  
08:32AM  
May-28-20 09:10AM  
May-27-20 08:51AM  
08:00AM  
May-11-20 06:53AM  
May-07-20 10:00PM  
10:56AM  
May-06-20 07:15PM  
04:05PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-16-20 04:05PM  
12:10PM  
Apr-10-20 08:49AM  
Apr-07-20 03:32PM  
Mar-26-20 09:00AM  
Mar-14-20 11:30AM  
Feb-26-20 04:05PM  
Feb-25-20 04:05PM  
Feb-20-20 11:13AM  
Feb-14-20 09:50AM  
Feb-13-20 09:45AM  
08:48AM  
07:00AM  
Feb-10-20 12:38PM  
10:13AM  
Feb-06-20 12:31PM  
Jan-30-20 04:05PM  
Jan-22-20 09:20AM  
Jan-06-20 08:00AM  
Jan-02-20 04:01PM  
09:35AM  
Dec-31-19 08:58AM  
Dec-27-19 12:00PM  
Dec-26-19 09:00AM  
Dec-25-19 11:30AM  
Dec-23-19 08:33AM  
Dec-19-19 07:34PM  
Dec-18-19 09:23AM  
Dec-13-19 08:39AM  
Dec-10-19 09:15AM  
08:33AM  
Dec-09-19 10:20AM  
Dec-03-19 08:51AM  
Nov-29-19 09:39AM  
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DENNER ALEXANDER JDirectorMar 10Buy10.5475,000790,50016,390,000Mar 10 07:06 PM
DENNER ALEXANDER JDirectorMar 08Buy10.30150,0001,545,00016,315,000Mar 10 07:06 PM
DENNER ALEXANDER JDirectorMar 05Buy10.01175,0001,751,75016,165,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 04Buy10.00250,0002,500,00015,990,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 03Buy10.02350,0003,507,00015,740,000Mar 05 07:19 PM
DENNER ALEXANDER JDirectorMar 02Buy9.56500,0004,780,00015,390,000Mar 02 08:18 PM
DENNER ALEXANDER JDirectorMar 01Buy9.60344,9003,311,04014,890,000Mar 02 08:18 PM
DENNER ALEXANDER JDirectorFeb 26Buy9.20505,1004,646,92014,545,100Mar 02 08:18 PM
Owens Edward PDirectorFeb 26Buy8.903,00026,700218,954Mar 02 04:41 PM
MCCOURT Thomas APresidentFeb 26Sale9.1114,685133,780471,577Mar 02 04:40 PM
Mallon MarkChief Executive OfficerFeb 26Sale9.1130,675279,449470,605Mar 02 04:37 PM
Kilroy ConorSVP, GC & SecretaryFeb 26Sale9.116,98963,670122,336Mar 02 04:36 PM
Consylman GinaSVP, CFO & TreasurerFeb 26Sale9.1118,406167,679336,244Mar 02 04:34 PM
Shetzline MichaelCMO, SVP & Head of Drug Devt.Feb 26Sale9.114,43940,439160,859Mar 02 04:44 PM
Rickard JasonSVP, Chief Operating OfficerFeb 26Sale9.1113,651124,361306,682Mar 02 04:43 PM
Owens Edward PDirectorFeb 25Buy9.115,00045,550215,954Feb 26 05:15 PM
Owens Edward PDirectorFeb 24Buy9.267,00064,820210,954Feb 26 05:15 PM
MCCOURT Thomas APresidentDec 14Option Exercise9.8999,988988,881421,720Dec 16 04:49 PM
MacDonald KellyChief Accounting OfficerDec 04Option Exercise9.125,63951,42898,680Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerDec 04Sale12.505,63970,48893,041Dec 08 04:01 PM
MacDonald KellyChief Accounting OfficerNov 11Option Exercise9.313,56133,15396,602Nov 13 04:02 PM
MacDonald KellyChief Accounting OfficerNov 11Sale11.753,56141,84293,041Nov 13 04:02 PM
Kilroy ConorSVP, GC & SecretaryNov 09Sale10.928369,129128,833Nov 10 04:09 PM
Consylman GinaSVP, CFO & TreasurerNov 09Sale10.921,41515,452269,699Nov 10 04:03 PM
Rickard JasonSVP, Chief Operating OfficerNov 09Sale10.923944,302235,382Nov 10 04:12 PM
MacDonald KellyChief Accounting OfficerNov 09Sale10.9292510,10193,041Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerNov 06Sale11.251,87221,06093,966Nov 10 04:10 PM
MacDonald KellyChief Accounting OfficerOct 08Sale10.5022,714238,49795,838Oct 13 04:03 PM
McHugh JulieDirectorSep 08Sale9.777,95077,672123,107Sep 09 06:26 PM
Rickard JasonSVP, Chief Operating OfficerAug 17Sale10.146896,986235,776Aug 19 04:05 PM
MacDonald KellyChief Accounting OfficerAug 17Sale10.145755,830118,552Aug 19 04:01 PM
OLANOFF LAWRENCE SDirectorJun 10Sale10.0611,350114,18168,629Jun 12 04:32 PM
Rickard JasonSVP, Chief Operating OfficerMay 11Sale10.355105,278234,580May 13 05:23 PM
MCCOURT Thomas APresidentMay 11Sale10.351,69717,564319,847May 13 05:22 PM
MacDonald KellyChief Accounting OfficerMay 11Sale10.351,15311,934118,147May 13 05:20 PM
Mallon MarkChief Executive OfficerMay 11Sale10.3523,206240,182501,280May 13 05:21 PM
Kilroy ConorSVP, GC & SecretaryMay 11Sale10.357167,411128,921May 13 05:19 PM